Formycon AG Stock
Price
Target price
€50.10
€50.10
1.110%
0.55
1.110%
€100.00
18:01 / Tradegate
WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Formycon AG is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Formycon
sharewise wants to provide you with the best news and tools for Formycon, so we directly link to the best financial data sources.
Financials
News
EQS-News: Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
EQS-News: Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
EQS-News: Formycon reports a strong first half-year with multiple milestones achieved
EQS-News: Formycon reports a strong first half-year with multiple milestones achieved
EQS-News: Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
EQS-News: Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
EQS-News: Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
EQS-News: Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
EQS-News: Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
EQS-News: Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
EQS-News: Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
EQS-News: Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
EQS-News: Formycon reports on the results of the Annual General Meeting
EQS-News: Formycon reports on the results of the Annual General Meeting
EQS-News: Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
EQS-News: Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
EQS-News: MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
EQS-News: MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
EQS-News: Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
EQS-News: Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
EQS-News: Formycon hosts conference call on the results of the first quarter 2024
EQS-News: Formycon hosts conference call on the results of the first quarter 2024
EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
EQS-News: Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
EQS-News: Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)